Equities Analysts Offer Predictions for IPA FY2025 Earnings

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) – Research analysts at HC Wainwright increased their FY2025 earnings estimates for ImmunoPrecise Antibodies in a research note issued on Monday, March 31st. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.17) per share for the year, up from their previous forecast of ($0.27). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for ImmunoPrecise Antibodies’ current full-year earnings is ($0.27) per share. HC Wainwright also issued estimates for ImmunoPrecise Antibodies’ Q4 2025 earnings at ($0.02) EPS, Q1 2026 earnings at ($0.03) EPS, Q2 2026 earnings at ($0.02) EPS, FY2026 earnings at ($0.08) EPS and FY2027 earnings at $0.01 EPS.

Separately, Benchmark reaffirmed a “speculative buy” rating and set a $3.00 price target on shares of ImmunoPrecise Antibodies in a research note on Tuesday.

ImmunoPrecise Antibodies Stock Up 5.2 %

IPA opened at $0.38 on Thursday. The firm has a market cap of $11.78 million, a P/E ratio of -0.49 and a beta of 0.09. The business’s fifty day simple moving average is $0.43 and its 200 day simple moving average is $0.47. ImmunoPrecise Antibodies has a 52 week low of $0.27 and a 52 week high of $1.50. The company has a quick ratio of 0.85, a current ratio of 1.01 and a debt-to-equity ratio of 0.36.

ImmunoPrecise Antibodies (NASDAQ:IPA) last announced its earnings results on Friday, March 28th. The company reported ($0.06) EPS for the quarter, meeting analysts’ consensus estimates of ($0.06). ImmunoPrecise Antibodies had a negative return on equity of 73.74% and a negative net margin of 114.50%. The firm had revenue of $4.23 million for the quarter, compared to analysts’ expectations of $6.59 million.

Institutional Investors Weigh In On ImmunoPrecise Antibodies

An institutional investor recently raised its position in ImmunoPrecise Antibodies stock. Ingalls & Snyder LLC increased its holdings in shares of ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) by 20.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,558,892 shares of the company’s stock after buying an additional 263,451 shares during the quarter. Ingalls & Snyder LLC owned about 5.41% of ImmunoPrecise Antibodies worth $996,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 6.70% of the company’s stock.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.